Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

81. Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis Full Text available with Trip Pro

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis 29147577 2019 01 30 2059-7029 2 Suppl 1 2017 ESMO open ESMO Open Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. e000119 10.1136/esmoopen-2016-000119 Vansteenkiste Johan J Respiratory Oncology Unit, Department of Respiratory Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. eng Editorial 2017 03 07 England ESMO Open 101690685 2059-7029 2016 11 27 2017 01 11 2016

2017 ESMO open

82. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer Full Text available with Trip Pro

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC.In this multicentre phase II study, patients with advanced (...) or recurrent non-squamous NSCLC, which had progressed after platinum-containing chemotherapy, were treated with nivolumab 3 mg/kg, intravenously every 2 weeks until progressive disease or unacceptable toxicity was observed. The primary end point was independent radiology review committee (IRC) assessed overall response rate (ORR) and the secondary endpoints included ORR (investigator assessed), progression-free survival (PFS), overall survival (OS), duration of response, time to response, best overall

2017 ESMO open

83. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24]

[Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56 [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): addendum zum auftrag A16-24; auftrag A16-56. [Nivolumab (renal cell carcinoma) - addendum to commission A16-24] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 438. 2016 Final publication URL Indexing Status

2017 Health Technology Assessment (HTA) Database.

84. [Nivolumab (NSCLC) - addendum to commission A16-25]

[Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57 [Nivolumab (NSCLC) - addendum to commission A16-25] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): addendum zum auftrag A16-25; auftrag A15-57. [Nivolumab (NSCLC) - addendum to commission A16-25] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 439. 2016 Final publication URL Indexing Status Subject indexing

2017 Health Technology Assessment (HTA) Database.

85. Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Grössmann N Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions The treatment of nivolumab offers durable responses, 31.1% demonstrated

2017 Health Technology Assessment (HTA) Database.

86. Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V

Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Plattenepithelkarzinom des Kopf-Hals- Bereichs) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-24 Nivolumab (squamous cell carcinoma of the head and neck) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-24 Version 1.0 Nivolumab (squamous cell carcinoma of the head and neck) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Benefit

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

87. Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-29 Nivolumab (...) (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-29 Version 1.0 Nivolumab (urothelial carcinoma) 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 3 July 2017

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

88. Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Melanom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-27 (...) Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A17-27 Version 1.0 Nivolumab (melanoma) 13 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 June

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

89. Evaluation of the clinical efficacy of cabozantinib and nivolumab in previously treated renal cell carcinoma

Evaluation of the clinical efficacy of cabozantinib and nivolumab in previously treated renal cell carcinoma Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2017 PROSPERO

90. Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer) [Cochrane protocol]

Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer) [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

91. Benefit and risk in summary of nivolumab in non-small cell lung cancer: a single arm meta-analysis of non-comparative clinical study and randomized controlled trial

Benefit and risk in summary of nivolumab in non-small cell lung cancer: a single arm meta-analysis of non-comparative clinical study and randomized controlled trial Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2017 PROSPERO

92. OPDIVO - Nivolumab

OPDIVO - Nivolumab Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated to include post

2017 Health Canada - Drug and Health Product Register

93. Nivolumab in advanced melanoma treament

Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Nivolumab in advanced melanoma treament Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L Citation Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Nivolumab in advanced melanoma treament. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (...) (IECS). Informe de Respuesta Rapida No. 480. 2016 Authors' conclusions Moderate quality evidence showed that the use of nivolumab, when compared with dacarbazine in patients with advanced melanoma (metastatic or inoperable) would increase survival rate at one year and progression-free survival as first line. Although its use as single-agent or in combination with ipilimumab showed an increased progression-free survival, the lack of information on its impact on overall survival or comparative studies

2017 Health Technology Assessment (HTA) Database.

94. Nivolumab for the treatment of non-small cell lung cancer

Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Nivolumab for the treatment of non-small cell lung cancer Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Nivolumab for the treatment of non-small cell lung cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 479. 2016 Authors' conclusions The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated

2017 Health Technology Assessment (HTA) Database.

95. Nivolumab for previously treated advanced renal cell carcinoma

Nivolumab for previously treated advanced renal cell carcinoma Niv Nivolumab for pre olumab for previously treated viously treated advanced renal cell carcinoma advanced renal cell carcinoma T echnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta417 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for previously treated advanced renal cell carcinoma (TA417) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents 1 Recommendations 4 2 The technology 5 3

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

96. Nivolumab for the treatment of renal-cell carcinoma

Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, López A, Pichon (...) -Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L. Nivolumab for the treatment of renal-cell carcinoma. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 491. 2016 Authors' conclusions No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage. High-quality evidence, coming from a single study in patients with clear cell histology, indicates

2016 Health Technology Assessment (HTA) Database.

97. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35. [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

2016 Health Technology Assessment (HTA) Database.

98. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Cologne

2016 Health Technology Assessment (HTA) Database.

99. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Cologne

2016 Health Technology Assessment (HTA) Database.

100. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line

Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSRIC. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Nivolumab and ipilimumab are two drugs used to treat renal cell carcinoma, which is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Nivolumab

2016 Health Technology Assessment (HTA) Database.